COT Well-positioned with Adaptable Technology

NY, NY—(7/15/2013) – Critical Outcome Technologies’ CEO Dr. Wayne Danter took time to update the investment community on COT’s recent news and progress.  During his in-depth interview with The Wall Street Analyst, Dr. Danter discusses the first commercial project from their core technology, COTI-2.  He believes it will be in phase 1 by the end of the year and foresees the trends in the sector going towards gene therapies.  In addition, he compares the way people will be able to access their technologies to the way consumers access iTunes, via a web portal.  Dr. Danter also talks about his background and experience as well as management’s key goal of partnering their lead asset and rolling out the CHEFIRM application. Dr. Danter adds that COT is not a one-trick pony: their technology allows them to pursue multiple projects simultaneously, which he feels sets them apart from other bio-tech companies.


For More Information Please Contact:

Critical Outcome Technologies Inc. Dr. Wayne Danter
President & CEO Tel:519‐858‐5157

Heisler Communications
Trevor Heisler
Investor Relations
Tel: 416‐500‐8061

Follow @CriticalOutcome on Twitter at

About author

This article was written by The Wall Street Analyzer

The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum. On one hand our financial experience gives us the ability to identify promising, off the grid companies before they are uncovered by the rest of the market, and on the other hand our media experience allows us to produce interviews which appeal to a large audience because we provide a format in which more investors can understand a featured companies' upside. Our philosophy is to turn stock tickers into stories, ideas into headlines, and technical and financial data into easy to understand tidbits, easier to digest and therefore consumed by a larger audience. These interviews provide a jumping off point for investors to do further research into a prospective company. Our editorials seek to provide an out-of-the-box perspective found in few other financial sites.